Shlevin Harold H.

Director Shlevin sold 175,790 shares (94.0% of holdings) for $1.1M across 8 transactions on 2025-12-08 to 2025-12-09

Harold Shlevin, a director at Galectin Therapeutics, executed 8 separate sales totaling 175,790 shares for $1,055,311.14 at an average price of $6.00 per share, reducing his stake from 186,996 shares to 11,206 shares—a 94.0% reduction in holdings. The sales occurred at prices ranging from $5.95 to $6.27 per share, near the 52-week high of $6.30 and $0.81 above the current price of $5.49. The company is unprofitable with a net loss of $8,184,000.00 over the most recent full fiscal year, and Shlevin's prior buy activity at this ticker (1 prior trade in December 2024) showed positive 90-day returns of 31.0%, suggesting his historical timing at GALT has been favorable. The near-complete liquidation of a director's position during an unprofitable period, at prices near 52-week highs, warrants investor attention to underlying business dynamics and management confidence signals.

Director Shlevin bought 6,500 GALT shares at $1.16 on 12/30/24; stock down 55.4% in 30 days; 3 other insiders also bought in past 14 days

Director Harold Shlevin purchased 6,500 shares for $7,540.00 at $1.16, increasing his holdings by 74.7% to 15,206 shares—a material increase in his ownership position at Galectin Therapeutics. This transaction occurred as the stock trades 69.3% below its 52-week high and has declined 55.4% over the past 30 days, while the company reported a full fiscal year net income of $-11,220,000.00. The filing shows a cluster pattern with 3 other insiders purchasing within the same 14-day window, suggesting coordinated management confidence during a period of significant share-price weakness. The timing and scale of these concurrent insider purchases—particularly the substantial relative increase in Shlevin's stake—merit close attention given the company's unprofitable status and the magnitude of recent price deterioration.